Related Experiment Videos
Interleukin 7 worsens graft-versus-host disease
Manoj L Sinha1, Terry J Fry, Daniel H Fowler
1Pediatric Oncology Branch, Experimental Transplantation and Immunology Branch, National Cancer Institute, and Veterinary Resources Program, National Institutes of Health, Bethesda, MD 20892, USA.
Blood
|September 20, 2002
Summary
Interleukin-7 (IL-7) enhances immune reconstitution after bone marrow transplantation (BMT) but increases graft-versus-host disease (GVHD) severity. IL-7 is most beneficial in T cell-depleted BMT, improving immune competence with reduced toxicity.
Area of Science:
- Immunology
- Transplantation Biology
Background:
- Impaired immune reconstitution is a major challenge in allogeneic bone marrow transplantation (BMT).
- Enhancing thymopoiesis is crucial for improving immune recovery post-BMT.
- Interleukin-7 (IL-7) is a potent cytokine that promotes thymopoiesis.
Purpose of the Study:
- To investigate the effects of recombinant human IL-7 (rhIL-7) on immune reconstitution and graft-versus-host disease (GVHD) in a murine allogeneic BMT model.
- To determine the optimal setting for IL-7 administration in BMT to maximize immune restoration while minimizing GVHD.
Main Methods:
- Administration of rhIL-7 in a murine parent into F1 allogeneic BMT model.
- Evaluation of clinical signs and histologic features of GVHD.
- Assessment of thymic function in T cell-depleted (TCD) and T cell-replete BMT settings.
Main Results:
- rhIL-7 lowered the T-cell dose threshold for inducing GVHD and increased tissue damage.
- rhIL-7 enhanced thymic function in TCD BMT recipients.
- IL-7 did not improve thymic function in T cell-replete BMT, likely due to graft-versus-host reaction-induced thymic toxicity.
Conclusions:
- IL-7 can enhance immune reconstitution but exacerbates GVHD in allogeneic BMT.
- Clinical use of IL-7 in BMT should be restricted to T cell-depleted settings to maximize immune benefits and minimize toxicity.